Breast cancer treatment with dendritic cells in Germany
Don't know where to start? Leave us a request, and the Booking Health team will arrange your trip for treatment in Germany, where you will improve the quality of life and health.
Dendritic cell breast cancer treatment is effective in almost all patients since a patient’s anti-cancer immunity is activated after vaccination. Individually manufactured vaccines with dendritic cells improve treatment results in different clinical situations: after surgery to remove a tumor, in the lymph nodes affection, in the presence of distant metastases, with cancer resistance to hormone therapy and chemotherapy. Vaccination prevents the recurrence in the early stages of the disease or helps to control it for a long time in advanced cancer. In German hospitals, this method of treatment demonstrates excellent success rates.
Content
- When breast tumors are treated with dendritic cells
- How the treatment is carried out
- Results of vaccination with dendritic cells in breast cancer
- How to undergo breast cancer treatment with dendritic cells in Germany
Dendritic cell therapy for breast cancer involves using the patient's dendritic cells to create a targeted immune response against cancer cells. These modified cells help the immune system recognize and attack breast cancer cells more effectively, potentially improving outcomes and reducing recurrence.
The benefits include personalized treatment, minimal side effects, and the potential for long-term remission. This therapy can be particularly effective for patients with advanced or metastatic breast cancer, offering a new avenue of hope when traditional treatments have failed.
While generally safe, some risks include mild side effects like fever and fatigue. Rarely, patients may experience more severe immune reactions. It is crucial to have the therapy administered in specialized clinics under the supervision of experienced professionals.
Results can vary; some patients may see improvements within a few weeks, while others may take several months. Continuous monitoring and follow-up are essential to assess the effectiveness and make any necessary adjustments to the treatment plan.
When breast tumors are treated with dendritic cells
In breast cancer, advancements in treatment options have led to improved survival rates, consequently extending life expectancy for many cancer patients. Immunotherapy can start quite early, at clinical stages I-II:
- When the size of the primary tumor is up to 5 cm, and when the woman will undergoes surgical treatment
- If only the axillary lymph nodes are affected
- In the absence of distant metastases
Breast tumors have long been considered non-immunogenic, so surgery, chemotherapy, radiation therapy, and hormonal therapy were preferred. However, a growing number of modern clinical studies demonstrate a significant antitumor response after the administration of dendritic cells.
«German doctors often supplement the standard treatment protocol for early-stage breast cancer with DC vaccination, thus achieving better results.»
The second area of administering such vaccines is advanced cancer, including stage 4 cancer, especially in the development of resistance to hormonal drugs and chemotherapy. In such a clinical situation, immunotherapy is aimed at better control of the disease: it prevents metastasizing and suppresses the growth of already existing distant metastases. An additional advantage is the absence of serious side effects typical for chemotherapy. Also, a woman does not need to take the drug daily: the vaccine is administered only a few times.
How the treatment is carried out
Dendritic cell therapy for breast cancer is an outpatient procedure. Before it begins, the woman visits the hospital several times:
- To make sure she has indications for this type of treatment. Immune therapy is most effective in women with tumors that express mutant p53 or Ki-67 and also have an HLA-A2 molecule on the surface. Immune therapy is also indicated for women with triple-negative cancer. Before starting a vaccination course, genetic analysis is performed to detect these changes.
- To donate blood, from which doctors will manufacture an individual anti-cancer vaccine. In German clinics, leukapheresis is carried out instead of the usual donation of whole blood. Leukapheresis is the isolation of leukocytes from the blood. Dendritic cells originate from a type of leukocytes, namely monocytes.
The dendritic cells are cultivated in the laboratory for several days. They are processed with growth factors and differentiation factors and "get acquainted" with tumor cells. Due to this, the future vaccine will consist of a large number of specialized dendritic cells trained to find and destroy the tumor in a particular patient.
The breast cancer vaccine is administered 3 to 5 times, with an interval of several weeks. It is a subcutaneous injection that is well tolerated. The most severe side effects are local redness, soreness at the injection site, chills, muscle pain, and headache. As a rule, doctors prefer to inject the drug closer to the location of the primary tumor and regional lymph nodes. It speeds up the development of the immune response.
In addition, young women can receive the cervical cancer vaccine because a number of clinical studies have found a link between cervical cancer and breast cancer. Cervical cancer often develops against the background of infection with the human papillomavirus (HPV), and vaccination aims to protect a woman from this virus. The drug is administered from 1 to 3 times. After completion of the course, the risk of developing cervical cancer is reduced by 70-90%. Vaccination against cervical cancer has one obligatory condition: the woman must not be infected with HPV at the time of treatment start.
Results of vaccination with dendritic cells in breast cancer
The use of dendritic cells in the treatment of breast cancer contributes to better control of the disease in the advanced stages or significantly reduces the risk of recurrence in the early stages. In cancer stages 1 and 2, the vaccine is administered 3 to 5 times after surgical removal of the tumor. This is enough to form a stable anti-cancer immunity. In the future, the body will independently renew the population of leukocytes responsible for the destruction of malignant cells. The woman will undergo regular follow-up examinations but will not need additional treatments.
«Regardless of the stage of breast cancer, up to 90% of women respond to the DC vaccine.»
In the advanced stages of breast cancer, the vaccine is injected less frequently, up to once every few months. At the same time, the course of treatment is longer: due to good tolerability and high efficiency, it can last for years. After vaccination, a significant increase in the level of antigen-specific T-lymphocytes against cancer cells is detected in the blood of patients. This means that the immune system has saved information about the tumor and immediately destroys existing and new metastases. T-lymphocytes will be constantly present in the blood, ready to destroy any number of malignant cells. At the same time, the chance of prolonging life and achieving cancer control increases by 15-20% since the antitumor response persists for a long time.
How to undergo breast cancer treatment with dendritic cells in Germany
In most countries, women cannot receive DC therapy for breast cancer, as they are treated according to the standard therapeutic protocol. This is only possible if a woman voluntarily participates in a clinical study. Thus, undergoing modern treatment in Germany is a suitable alternative. German clinics actively use immunotherapy and administer individual anti-cancer vaccines at all stages of breast cancer.
Dendritic cell therapy for breast cancer in Germany offers a promising alternative to traditional treatments, potentially improving prognosis for patients with metastatic disease or those seeking options beyond conventional approaches. This innovative therapy can be combined with other treatments like chemotherapy or hyperthermia to enhance its effectiveness in targeting tumor cells and alleviating symptoms. While costs may vary, increasing awareness about this treatment option and its potential benefits is crucial, as is the importance of regular screening and early detection tests in improving overall outcomes for breast cancer patients.
You can find information about specialized healthcare facilities and the average cost of treatment with dendritic cells on the Booking Health website. For more than 12 years, the company has been helping women with breast cancer from all over the world receive treatment in Germany, including sparing and reconstructive surgeries, cryoablation, immunotherapy, targeted therapy, etc.
In addition to providing information about clinics, the tasks of Booking Health include:
- Consultation on modern methods of treatment, including DCT for cancer
- Direct communication with the attending physician; if necessary, arranging a distant consultation
- Making an appointment at the clinic without being on a long waiting list
- Preliminary preparation of a treatment program without repeating previous examinations
- Ensuring the favorable cost of clinic services, exclusion of additional taxes for foreign patients (saving up to 50%)
- Assistance in purchasing and sending medicines in order to continue treatment in your country
- Communication with clinic and doctor after the treatment completion
- Control of prices for medical services and invoices from the clinic
- Organization of additional examinations or treatments, if necessary
- Top-level service: booking accommodation, tickets, transfer, etc.
- Services of an interpreter and personal medical coordinator
- Translation of medical reports and doctor’s recommendations
You can make an appointment in the desired hospital on the Booking Health website. If you have any questions, feel free to fill out the "Send a request" form and wait for a call from the medical coordinator.
Choose treatment abroad and you will for sure get the best results!
See the interview for more information:
INNOVATIVE DENDRITIC CELL TREATMENT IN GERMANY – interview with Prof. Dr. med. Frank Gansauge
Authors:
The article was edited by medical experts, board certified doctors Dr. Nadezhda Ivanisova and Dr. Vadim Zhiliuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
Read:
Dendritic cell therapy in cancer treatment in Germany - Vaccination against cancer
Immunotherapy for breast cancer in Germany
Treatment of stage 4 breast cancer in Germany
The Main Types of Breast Cancer Treatment in Germany
